Future research involving larger, well-balanced cohorts and multicentre collaboration is necessary to validate the potential role of IL-21 and IL-22 as biomarkers and to better understand their involvement in the breast cancer pathogenesis. This evidence concerns the gene IL21 and breast cancer.